Abstracts

References

• Waxman S, Scher B M, Hellinger N, Scher W. Combination cytotoxic-differentiation therapy of mouse erythroleukemia cells with 5-fluorouracil and hexamethylene bisacetamide. Cancer Res 1990; 50: 3878–3887
   PubMed Web of Science ®Google Scholar
• Hozumi M, Waxman S. Design of combination differentiation therapy. Conference Publications, Status of Differentiation Therapy in Cancer, S. Waxman, G Rossi, F Takaku. Raven Press, New York 1991
   Google Scholar
• Waxman S, Wang S, Scher W, Scher B M. Combination cytotoxic-differentiation therapy of leukemia. Conference Publications. Status of Differentiation Therapy in Cancer, S Waxman, G Rossi, F Takaku. Raven Press, New York 1991
   Google Scholar
• Huang M E, Ye Y C, Chai JR. Use of all transretinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72: 567–572
   PubMed Web of Science ®Google Scholar
• Castaigne S, Chomienne C, Daniel M T. Ml-transretinoic acid as a differentiation therapy for acute promyelocytic leukemia: I. clinical results. Blood 1990; 76: 1704–1709
   PubMed Web of Science ®Google Scholar
• Warrell RP, Jr, Frankel S R, Miller WH, Jr. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-transretinoic acid). N Engl J Med 1991; 324: 1385–1393
   PubMed Web of Science ®Google Scholar
• De The H, Chomienne C, Lanotte M. The t(15; 17) translocation of acute promyelocytic leukaemia fuses the retinoic acid recep-tor-ce gene to a novel transcribed locus. Nature 1990; 347: 558–651
   PubMed Web of Science ®Google Scholar
• Kakizuka A, Miller WH, Jr, Umesono K. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses the RAR-alpha receptor with a novel putative transcription factor PML. Cell, in press
   Google Scholar
• Barnett M J, Eaves C J, Philips G L. Successful autografting in chronic myeloid leukaemia after maintenance of marrow in culture. Bone Marrow Transplant 1989; 4: 345–351
   PubMed Web of Science ®Google Scholar
• Fraser C C, Eaves C J, Szilvassy S J, Humphries R K. Expansion in vitro of retrovirally marked totipotent hematopoietic stem. Blood 1990; 76: 1071–1076
   PubMed Web of Science ®Google Scholar
• Sutherland H J, Eaves C J, Landsdorp P M. Differential regulation of primitive human hematopoietic cells in long-term cultures maintained on genetically engineered murine stromal cells. Blood, in press
   Google Scholar
• Otsuka T, Thacker J D, Hogge D E. Analysis of the effects of Interleukin-6 and Interleukin-3 on early hematopoietic events in long term cultures of human marrow. Exp Hematol, in press
   Google Scholar
• Hogge D E, Cashman J D, Humphries R K, Eaves C J. Differential and synergistic effects of human granulocyte-macrophage colony-stimulating factor and human granulocyte colony-stimulating factor on hematopoiesis in human long-term marrow cultures. Blood 1991; 77: 493–499
   PubMed Web of Science ®Google Scholar
• Otsuka T, Thacker J D, Eaves C J, Hogge D E. Differential effects of microenvironmentally presented interleukin 3 (TL-3) versus soluble growth factor on primitive human hematopoietic cells. J Clin Invest, in press
   Web of Science ®Google Scholar
• Eaves C J, Cashman J D, Kay R J. Mechanisms that regulate the cell cycle status of very primitive hematopoietic cells in long-term human marrow cultures. U. Analysis of positive and negative regulators produced by stromal cells within the adherent layer. Blood, in press
   Google Scholar
• Klingemann H-G, Eaves A C, Onetto N. Randomized trial of GM-CSF (2 hour versus 24 hour infusion) after autologous bone marrow transplantation (AuBMT) for Hodgkin's disease [abstract]. Exp Hematol 1991; 19: 558
   Web of Science ®Google Scholar
• Thomas E D, Storb R, Clift R A. Bone-marrow transplantation. Part I. N Engl J Med 1975; 292: 832–843
   PubMed Web of Science ®Google Scholar
• Thomas E D, Storb R, Clift R A. Bone-marrow transplantation. Part H. N Engl J Med 1975; 292: 895–902
   PubMed Web of Science ®Google Scholar
• Metcalf D. The granulocyte-macrophage colony-stimulating factors. Science 1985; 299: 16–22
   Google Scholar
• Nemunaitis J, Singer J W, Buckner C D. Use of recombinant human granulocyte-macrophage colony-stimulating factor in autologous marrow transplantation for lymphoid malignancies. Concise Report. Blood 1988; 72: 834–836
   PubMed Web of Science ®Google Scholar
• Nemunaitis J, Buckner C D, Appelbaum F R. Phase I/n trial of recombinant human granulocyte-macrophage colony-stimulating factor following allogeneic bone marrow transplantation. Blood 1991; 77: 2065–2071
   PubMed Web of Science ®Google Scholar
• Nemunaitis J, Rabinowe S N, Singer J W. Recombinant granulocyte macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med, in press
   PubMedGoogle Scholar
• Nemunaitis J, Singer J W, Buckner C D. Use of recombinant human granulocyte-macrophage colony-stimulating factor in graft failure after bone marrow transplantation. Blood 1990; 76: 245–253
   PubMed Web of Science ®Google Scholar
• Freedman A S, Takvorian T, Anderson K C. Autologous bone marrow transplantation in B-cell non-Hodgkin's lymphoma: very low treatment-related mortality in 100 patients in sensitive relapse. J Clin Oncol 1990; 8: 784–791
   PubMed Web of Science ®Google Scholar
• Jagannath S, Dicke K A, Armitage J O. High dose cyclophosphamide, carmustine and etoposide and autologous marrow transplantation for relapsed Hodgkin's disease. Ann Intern Med 1986; 104: 163–168
   PubMed Web of Science ®Google Scholar
• Pritchard J, Germond S, Jones D. Is high-dose melphalan of value in treatment of advanced neuroblastoma? Preliminary results of a randomized trial by the European Neuroblastoma Study Group. Proc Am Soc Clin Oncol 1986; 5: 205
   Google Scholar
• Socinski M A, Cannistras A, Elias A. Granulocyte-macrophage colony stimulating factor expands the circulating hematopoietic progenitor cell compartment in humans. Lancet 1988; 1: 1194–1198
   PubMed Web of Science ®Google Scholar
• Mazanet R, Elias A, Ayash L. Peripheral blood progenitor cells (PBPCs) added to bone marrow (BM) for hemopoietic rescue following high dose chemotherapy for solid tumors reduces morbidity and length of hospitalization. Proc ASCO 1991; 10: 324, C-1140
   Google Scholar
• Gianni A M, Bregni M, Siena S. Rapid and complete hemopoietic reconstitution following combined transplantation of autologous blood and marrow cells. A changing role for high dose chemo-radiotherapy. Hematol Oncol 1989; 7: 139–148
   PubMed Web of Science ®Google Scholar
• Peters W P, Kurtzberg J, Kirkpatrick G. GM-CSF primed peripheral blood progenitor cells (PBPC) coupled with autologous bone marrow transplantation (ABMT) will eliminate absolute leukopenia following high dose chemotherapy (HDC). Blood 1990; 76: 50a, (abstr 178), (Suppl 1)
   PubMedGoogle Scholar
• Elias A D, Ayash L, Anderson K. Hematologic support during high dose intensification for breast cancer: recruitment of peripheral blood progenitor cells (PBPC) by GM-CSF and chemotherapy. Blood 1990; 76: 536, (2135a), (Suppll)
   Google Scholar
• Hill R S, Mazza P, Amos D. Engraftment in 86 patients with lymphoid malignancy after autologous marrow transplantation. Bone Marrow Transplant 1989; 4: 69
   PubMed Web of Science ®Google Scholar
• Solberg L, Vilar D, Oles K. Thrombocytopenia following autologous marrow transplantation (ABMT). Blood 1990; 76: 567a, (abstr 2257), (Suppl 1)
   Google Scholar
• Amman K, Eder J, Elias A. High-dose cyclophosphamide, thioTEPA, and carboplatin intensification with autologous bone marrow support in patients with breast cancer responding to standard dose induction therapy. Proc ASCO 1990; 9: 10, C-33
   Google Scholar
• Gianni A M, Bregni M, Siena S. Recombinant human granulocyte-macrophage colony-stimulating factor reduces hematologic toxicity and widens clinical applicability of high-dose cyclophosamide treatment in breast cancer and non-Hodgkin's lymphoma. J Clin Oncol 1990; 8: 768–778
   PubMed Web of Science ®Google Scholar
• Winton E F, Rozmiarek S K, Jacobs PC. Marked increase in marrow and peripheral blood multilineage and megakaryocyte progenitor cells induced by short-course sequential recombinant human IL-3/GM-CSF in a non-human primate. Blood 1990; 76: 172a, (abstr 678), (Suppl 1)
   PubMedGoogle Scholar
• Socinski M A, Cannistra S A, Sullivan R. Human granulocyte-macrophage colony-stimulating factor induces the expression of the CDllb surface adhesion molecule on granulocytes in vivo. Blood 1988; 72: 691–697
   PubMed Web of Science ®Google Scholar
• Demetri G, Spertini O, Pratt E S. GM-CSF and G-CSF have different effects on expression of neutrophil adhesion receptors in vivo. Blood 1990; 76: 178a, (abstr 704), (Suppl l)
   PubMedGoogle Scholar
• Richman C M, Weiner R S, Yankee R A. Increase in circulating stem cells following chemotherapy in man. Blood 1976; 47: 1031–1039
   PubMed Web of Science ®Google Scholar
• Schwartzberg L, West W, Birch R. High dose cyclophosphamide (HD-CTX) or etoposide (HDVP-16) as mobilization chemotherapy for peripheral blood stem cell (PBSC) harvest. Blood 1990; 76: 564a, (abstr 2247), (Suppl 1)
   Google Scholar
• Osband M E, Carpinito G A, Levine S I. Successful Adoptive Immunotherapy of Metastatic Renal Cell Carcinoma with In Vitro Immunized Autologous Lymphocytes and Cimetidine. World J. Urol. 1986; 4: 217–221
   Web of Science ®Google Scholar
• Krane R J, Carpinito O, Ross S, Osband M E. Treatment of Stage IV Renal Cell Carcinoma with Autolymphocyte Therapy: Results of a Phase H Study. Urology 1990; 35: 417–422
   PubMedGoogle Scholar
• Osband M E, Lavin P T, Babayan R K. Effect of autolymphocyte therapy on survival and quality of life in patients with metastatic renal-cell carcinoma. Lancet 1990; 335: 994–998
   PubMed Web of Science ®Google Scholar
• Buzdar A U, Kau S W, Smith T L, Hortobagyi G N. Ten-year results of FAC adjuvant chemotherapy trial in breast cancer. Am J Clin Oncol (CCT) 1989; 12(2)123–128
   PubMed Web of Science ®Google Scholar
• Kau S W, Buzdar A, Fraschini G. Impact of adjuvant chemotherapy with FAC patients with × 10 positive nodes operable breast cancer. Proc Am Soc Clin Oncol 1989; 8: 30
   Google Scholar
• Hortobagyi G N, Ames F C, Buzdar A U. Management of stage m primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer 1988; 62: 2507–2516
   PubMed Web of Science ®Google Scholar
• Koh E H, Buzdar A U, Ames F C. Inflammatory carcinoma of the breast: Results of a combined modality approach-M.D. Anderson Cancer Center Experience. Cancer Chemother Pharmacol 1990; 27: 94–100
   PubMed Web of Science ®Google Scholar
• Hortobagyi G N, Frye, Buzdar A U. Complete remission (CR) in metastatic breast cancer (MBC): A thirteen year (YR) follow-up report. Proc Am Soc Clin Oncol 1988; 7: 37
   Google Scholar
• Fidler I J, Kripke M L. Metastasis results from preexisting variant cells within a malignant tumor. Science 1977; 197: 893–895
   PubMed Web of Science ®Google Scholar
• Norton L. Implications of kinetic heterogeneity in clinical oncology. Semin Oncol 1985; 12: 231–249
   PubMed Web of Science ®Google Scholar
• Skipper H E. Laboratory models: The historical perspective. Cancer Treat Rep 1986; 80: 3–7
   Google Scholar
• Frei E m, Teicher B A, Holden S A. Preclinical studies and clinical correlation of the effect of alkylating dose. Cancer Res 1988; 48: 6417–6423
   PubMed Web of Science ®Google Scholar
• Schabel F M. Concepts for the systemic treatment of micrometastases. Cancer 1975; 35: 15–24
   PubMed Web of Science ®Google Scholar
• Canellos G P, DeVita V T, Gold G L. Combination chemotherapy for advanced breast cancer: Response and effect on survival. Ann Intl Med 1976; 84: 389–392
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists' Group Collaboratve. Treatment of Early Breast Cancer: Worldwide Evidence in 1985–1990. A Systematic Overview of All Available Randomized Trials in Early Breast Cancer of Adjuvant Endocrine and Cytotoxic Therapy. Oxford University Press, New York 1990
   Google Scholar
• DeVita V T. The relationship between tumor mass and resistance to treatment of cancer. Cancer 1983; 51: 1209–1220
   PubMed Web of Science ®Google Scholar
• Luria S E, Delbruck M. Mutations of bacteria from virus sensitivity to virus resistance. Genetics 1943; 28: 491
   PubMedGoogle Scholar
• Law L W. Origin of resistance of leukaemic cells to folic acid antagonists. Nature 1952; 169: 628–629
   PubMed Web of Science ®Google Scholar
• Goldie J H. Scientific basis for adjuvant and primary (neoadjuvant) chemotherapy. Semin Oncol 1987; 14: 1–7
   PubMed Web of Science ®Google Scholar
• DeVita VT, Jr, Young R C, Canellos G P. Combination vs. single agent chemotherapy: A review of the basis for selection of drug treatment of cancer. Cancer 1975; 35: 98–110
   PubMed Web of Science ®Google Scholar
• Day R. Treatment sequencing, asymmmetry, and uncertainty: Protocol strategies for combination chemotherapy. Cancer Res 1986; 46: 3876–3885
   PubMed Web of Science ®Google Scholar
• Fisher B, Redmond C, Poisson R. Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 1989; 320: 822–828
   PubMed Web of Science ®Google Scholar
• The Ludwig Breast Cancer Study Group. Combination adjuvant chemotherapy for node-positive breast cancer. N Engl J Med 1988; 319: 677–683
   PubMed Web of Science ®Google Scholar
• Kardinal C G, Perry M C, Korzun A H. Responses to chemotherapy or chemohonnonal therapy in advanced breast cancer patients treated previously with adjuvant chemotherapy: A subset analysis of CALGB study 8081. Cancer 1988; 61: 415–419
   PubMed Web of Science ®Google Scholar
• Valagussa P, Brambilla C, Zambetti M, Bonadonna G. Salvage treatment after first relapse of breast cancer: A review. Third International Conference on Adjuvant Therapy of Primary Breast Cancer, St. GallenSwitzerland, March 2–5, 1988, 9
   Google Scholar
• DeVita VT, Jr. Dose-response is alive and well. J Clin Oncol 1986; 4: 1157–1159
   PubMed Web of Science ®Google Scholar
• Tannock I F, Boyd N F, DeBoer G. A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol 1988; 6: 1377–1387
   PubMed Web of Science ®Google Scholar
• Hryniuk W M. The importance of dose intensity in the outcome of chemotherapy. Important Advances in Oncology 1988, VT DeVita, Jr, S Hellman, SA Rosenberg. J.B. Lippincott, Philadelphia 1988; 121–141
   Google Scholar
• Norton L. A Oompertzian model of human breast cancer growth. Cancer Res 1988; 48: 7067–7071
   PubMed Web of Science ®Google Scholar
• Norton L, Simon R. Tumor size, sensitivity to therapy, and the design of treatment schedules. Cancer Treat Rep 1977; 61: 1307–1317
   PubMedGoogle Scholar
• Norton L, Simon R. The Norton-Simon hypothesis revisited. Cancer Treat Rep 1986; 70: 163–169
   PubMedGoogle Scholar
• Skipper H E. Analyses of muloarmed trials in which animals bearing different burdens of L1210 leukemia cells were treated with two, three, and four drug combinations delivered in different ways with varying dose intensities of each drug and varying average dose intensities. South Res Inst Booklet 1986; 7(42)87–92
   Google Scholar
• Buzzoni R, Bonadonna G, Valagussa P, Zambetti M. Sequential vs. alternating chemotherapy in the adjuvant treatment of breast cancer with more than three positive axillary nodes. Proc Am Soc Clin Oncol 1990; 9: 67
   Google Scholar
• Goldstein L J, Galski H, Fojo A. Expression of multidrug resistance gene in human tumors. J Natl Cancer Inst 1989; 81: 116–124
   PubMed Web of Science ®Google Scholar
• Adler A, Stein J A, Ben-Efraim S. Immunocompetence, immunosuppression and human breast cancer. Cancer 1980; 45: 2061–2083
   PubMed Web of Science ®Google Scholar
• Krown S E, Pinksy G M, Wanebo J H. Immunologic reactivity and prognosis in breast cancer. Cancer 1980; 46: 1746–1752
   PubMed Web of Science ®Google Scholar
• O'Connell M J, Ritts A E, Moertel C G. A controlled clinical and immunological evaluation of immunotherapy with BacillusCalmette-Guerin in patients with metastatic cancer. Cancer Clin Trials 1981; 4: 439–449
   PubMedGoogle Scholar
• Greenspan E M. Prior tuberculosis in long-term survivors of breast and ovarian cancer from a New York oncology practice (1954–1974). Mt Sinai J Med 1985; 52(6)465–468
   PubMed Web of Science ®Google Scholar
• Greenspan E M. In BCG an “orphan” drug suffering from chemotherapists' overkill. Cancer Invest 1986; 4(1)81–92
   PubMed Web of Science ®Google Scholar
• Alberts D S, Moon T E, Stephens R A. Randomized study of chemoimmunotherapy for advanced ovarian carcinoma. A preliminary report of a Southwest Oncology Group study. Cancer Treat Rep 1979; 63: 325–331
   PubMedGoogle Scholar
• Panettiere F J, Rogers A R, Chen T T. SWOG large bowel postoperative program. An update. Fourth International Conference on the Adjuvant Therapy of Cancer, Tucson, AZ, 1985, 94
   Google Scholar
• Guinan P, Totonchi E, Cripsin R. BCG immunotherapy in advanced prostate cancer. Immunotherapy of Human Cancer, WD Terry, SA. Rosenberg. Elsevier, North Holland 1982; 324–327
   Google Scholar
• Greenspan E M. Personal observation
   Google Scholar
• Silver R T. Recombinant inteferon-alpha for treatment of polycythemia vera (Letter). Lancet 1988; 13: 403
   Google Scholar
• Silver R T. A new treatment for polycythemia vera: recombinant interferon alfa. Blood 1990; 76: 664
   PubMed Web of Science ®Google Scholar
• Ariad S, Bezwoda W R. a-Interferon for polycythemia vera. Blood 1991; 77: 670
   PubMed Web of Science ®Google Scholar
• Cacciola E, Giustolisi R, Guglielmo. Recombinant interferonor in the treatment of polycythemia vera (Correspondence). Blood 1991; 77(12)2790
   PubMed Web of Science ®Google Scholar
• Mattson W. High dose medroxyprogesterone-acetate treatment in advanced mammary carcinoma. Acta Radiol Oncol 1978; 17: 387–400
   Google Scholar
• DeLena M, Brambilla C, Valagussa P, Bonadonna G. High-dose medroxyprogesterone acetate in breast cancer resistant to endocrine and cytotoxic therapy. Cancer Chemother Pharmacol 1979; 2: 175–180
   PubMed Web of Science ®Google Scholar
• Tchekmedyian N S, Tait N, Abrams J. High-dose megestrol acetate in the treatment of advanced breast cancer. Sem Oncol 1988; 15: 44–49
   PubMed Web of Science ®Google Scholar
• Morgan L R, Donley P J, Savage J. High-dose megestrol acetate in advanced breast cancer: bioavailability, toxicity, and response. Proc Am Assoc Clin Radiol 1983; 24: 134
   Web of Science ®Google Scholar
• Muss H, Case L D, Capizzi R L. High-versus standard-dose megestrol acetate in women with advanced breast cancer: a Phase m trial of the Piedmont Oncology Association. J Clin Oncol 1990; 8: 1797–1805
   PubMed Web of Science ®Google Scholar
• Tchekmedyian N S, Tait N, Moody M. High-dose megestrol acetate: a possible treatment for cachexia. J Am Med Assoc 1987; 1195–1198
   Web of Science ®Google Scholar
• Loprinzi C L, Ellison N M, Schaid D J. Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. J Natl Cancer Inst 1990; 82: 1127–1132
   PubMed Web of Science ®Google Scholar
• Wiseman C, Presant C, Bouzaglou A. High-dose megestrol acetate (HDM) in breast and other cancers: Description of study and preliminary results. Proc Am Soc Clin Oncol 1988; 7: 34
   Google Scholar
• Wiseman C., Presant C, Kennedy P. Clinical efficacy of high-dose megestrol in metastatic breast cancer. Proc Am Assoc Clin Radiol 1991; 32: 182
   Google Scholar
• Wiseman C L, Buzdar A U, Blumenschien G R. Mitomycin C and megestrol acetate-an active second-line regimen for breast cancer patients refractory to previous treatment. Proc Am Assoc Clin Radiol 1978; 10: 371
   Google Scholar
• Focan C, Beauduin M, Lobelle J P. Lack of correlation between dose intensity of CMF with or without medroxyprogesterone acetate. Proc A Acad Clin Radiol 1990; 31: 184
   Google Scholar
• Wils J A, Bron H, VanLange L. A randomized comparative trial of combined versus alternating therapy with cytostatic drugs and high-dose medroxyprogesterone acetate in advanced breast cancer. Cancer 1985; 56: 1325–1331
   PubMed Web of Science ®Google Scholar
• Wang L, Yang C-PH, Trail P. Reversal of the MDR Phenotype with megestrol acetate. Proc Am Assoc Clin Radiol. 1991; 32: 377
   Google Scholar
• Fleming G F, Amato J M, Agresti M. Reversal of multidrug resistance by megestrol acetate. Proc Am Assoc Clin Radio 1991; 32: 279
   Google Scholar
• Hanna MG, Jr, Brandhorst J S, Peters L C. Active-specific immunotherapy of residual micrometastasis: An evaluation of sources, doses and ratios of BCO with tumor cells. Cancer Immunol Immunother 1979; 7: 165–173
   Web of Science ®Google Scholar
• Hoover HC, Jr, Surdyke M, Dangel R B. Delayed cutaneous hypersensitivity to autologous tumor cells in colorectal cancer patients immunized with an autologous tumor cell: Bacillus Calmette-Guerin vaccine. Cancer Res 1984; 44: 1671–1676
   PubMed Web of Science ®Google Scholar
• Hoover HC, Jr, Surdyke M G, Dangel R B. Prospectively randomized trial of adjuvant active-specific immunotherapy for human colorectal cancer. Cancer 1985; 55: 1236–1243
   PubMed Web of Science ®Google Scholar
• Stahelin H, Von Wartburg A. From podophyllotoxin glucoside to etoposide. Progr Drug Res 1989; 33: 169–266
   PubMedGoogle Scholar
• Current perspectives on teniposide (VM-26): an international conference. Sem Oncol 1991; 18: 1–102, suppl 4
   PubMedGoogle Scholar
• Rivera G K, Evans W E. Clinical trials of teniposide (VM-26) in childhood acute lymphocytic leukemia. Sem Oncol 1991; 18: 51–58, Suppl 4
   Google Scholar
• Grossberg H, Opfell R, Glick J. Treatment of advanced refractory lymphoma with teniposide and lomustine. Cancer Treat Rep 1987; 71: 215–216
   PubMedGoogle Scholar
• Hansen H H, Domberoowsky P, Hansen M, Bork E. Teniposide in the treatment of small cell lung cancer: a review. Sem Oncol 1991; 18: 74–80, Suppl 4
   Google Scholar
• Pritchard J, Kiely E, Rogers D W. Long-term survival after advanced neuroblastoma (Lett). N Engl J Med 1987; 317: 1026–1027
   PubMed Web of Science ®Google Scholar
• Cheung N-KV, Heller G. Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survial in metastatic neuroblastoma. J Clin Oncol 1991; 9: 1050–1058
   PubMed Web of Science ®Google Scholar
• Rozencweig M, Von Hoff D D, Henney J, Muggia F M. VM 26 and 16–213: a comparative analysis. Cancer 1977; 40: 334–342
   PubMed Web of Science ®Google Scholar
• Muggia F M, Selawry O S, Hansen H H. Clinical studies with a new podophyllotoxin derivative, epipodophyllotoxin, 4′-demethyl-9-(4,5–0–2-thenylidene-beta-D-glucopyranoside) (NSC-122819). Cancer Chemother Rep 1971; 55: 575–581
   PubMedGoogle Scholar
• Sklansky B D, Mann-Kaplan R S, Reynold A F. 4′-Demethyl-epipodophyllotoxin-beta-D-thenylidene-glucoside (PTG) in the treatment of malignant intracranial neoplasms. Cancer 1974; 33: 460–467
   PubMed Web of Science ®Google Scholar
• McVie JG. Teniposide (VM-26) in brain tumors. Sem Oncol 1991; 18: 85–88, Suppl 4
   Google Scholar
• Muggia F M, Russel C A. New chemotherapies for ovarian cancer: systemic and intraperitoneal podophyllotoxins. Cancer 1991; 67: 225–230
   PubMed Web of Science ®Google Scholar
• Mathe G. Article in Paris Match 13 March, 1971
   Google Scholar
• Greenspan E M, Colsky J, Schoenbach B. Response of patients with advanced neoplasms to the intravenous administration of alpha-peltatin. J Natl Cancer Inst 1954; 14: 1257–1275
   PubMed Web of Science ®Google Scholar
• Brown T, Havlin K, Weiss G. A phase I trial of Taxol (NSC 125973) given by a 6-hour intravenous infusion. J Clin Oncol, in press
   Google Scholar
• Wall J, Burris H, Rodriguez G. Phase I trial of topotecan (SKF 104864) in patients with refractory solid tumors. Proc Am Soc Clin Oncol 1991; 10: 98
   Google Scholar
• Rodriguez G, Havlin K, Burris H. Phase I clinical trial of ilmofosine, a novel antitumor agent. Proc Am Soc Clin Oncol 1991; 10: 114
   Google Scholar
• Rowinsky E K, Cazenave L A, Donehower R C. Taxol: A novel investigational antimictotubule agent. J Nad Cancer Inst 1990; 82: 1247–1259
   PubMed Web of Science ®Google Scholar
• Manfredi J J, Horowitz SB. Taxol An antimitotic agent with a new mechanism of action. Pharmacol Ther 1984; 25: 83–125
   PubMed Web of Science ®Google Scholar
• Davidson D E, Grenan M M, Sweeney T R. Biological characteristics of some improved radioprotectors. Radiation Sensitizers, LW Brody. Masson, New York 1980; 309–320
   Google Scholar
• Yuhas J M, Storer J B. Differential chemoprotection of normal and malignant tissues. J Nad Cancer Int 1969; 42: 331–335
   PubMed Web of Science ®Google Scholar
• Yuhas J M. Differential protection of normal and malignant tissue against the cytoxic effects of mechlorethamine. Cancer Treat Rep 1974; 63: 971–976
   Google Scholar
• Yuhas J M, Spellman J M, Culo F. The role of WR-2721 in radiotherapy and/or chemotherapy. Cancer Clin Trials 1980; 3: 211–216
   PubMedGoogle Scholar
• Yuhas J M, Spellman J M, Jordan S W. Treatment of tumors with the combination of WR-2721 and cis-dichlorodiammine-platinum (JJ) or cyclophosphamide. Br J Cancer 1980; 42: 574–585
   PubMed Web of Science ®Google Scholar
• Yuhas J M, Culo F. Selective inhibition of the nephrotoxicity of cis-dichlorodiamineplatinum (JJ) by WR-2721 without altering its antitumor properties. Cancer Treat Rep 1980; 64: 57–64
   PubMedGoogle Scholar
• Wasserman T H, Phillips T L, Ross G, Kane J J. Differential protection gainst cytotoxic chemotherapeutic effects on bone marrow CFUs by WR-2721. Cancer Clin Trials 1981; 4: 3–6
   PubMedGoogle Scholar
• Millar J L, McElwain T J, Clutterbuck R P, West F A. The modification of melphalan toxicity in tumor-bearing mice, by S-2-(3-aminopropylamino)-ethylphosphorothioic acid (WR-2721). Am J Clin Oncol 1982; 5: 321–328
   PubMed Web of Science ®Google Scholar
• Valeriote F, Sandra T. Protection and potentiation of nitrogen mustard cytotoxicity by WR-2721. Cancer Res 1982; 42: 4330–4331
   PubMed Web of Science ®Google Scholar
• Nagy B, Dale P J, Grdina D J. Protection against cis-diamminedichloroplatinum cytotoxicity and mutagenicity in V79 cells by 2-[(aminopropyl)amino]ethanethiol. Cancer Res 1986; 46: 1132–1135
   PubMed Web of Science ®Google Scholar
• Grdina D J, Sigdestad C P. Radiation protectors: the unexpected benefits. Drug Metabol Rev 1989; 20: 13–42
   PubMed Web of Science ®Google Scholar
• Milos L, Hunter N, Stephens C L, Peters L J. Inhibition of radiation carcinogenesis by S-2-(3-aminopropylamino) ethyl phosphorothioic acid. Cancer Res 1984; 44: 5567–5569
   PubMed Web of Science ®Google Scholar
• Calabro-Jones P M, Fahey R C, Smoluk G D, Ward J F. Alkaline phosphatase promotes radioprotection and accumulation of WR-1065 in V79–171 cells incubated in medium containing WR-2721. Int J Radiat Biol 1985; 47: 23–27
   Web of Science ®Google Scholar
• Calabro-Jones P M, Aguilera J A. Uptake of WR-2721 derivatives by cells in culture: Identification of the transported form of the drug. Cancer Res 1988; 48: 3634–3640
   PubMed Web of Science ®Google Scholar
• Smoluk G D, Fahey R C. Radioprotection of cells in culture by WR-2721 and derivatives: form of the drug responsible for protection. Cancer Res 1988; 48: 3641–3647
   PubMed Web of Science ®Google Scholar
• Glover D, Glick J H, Weiler C. WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma. J Clin Oncol 1987; 5(4)574–584
   PubMed Web of Science ®Google Scholar
• Mullman S, Glover D. Cisplatin neuropathy. Risk factors, prognosis and protection by WR-2721. Cancer 1988; 61: 2192–2195
   PubMed Web of Science ®Google Scholar
• Glover D, Glick J H, Weiler C. WR-2721 protects against the hematologic toxicity of cyclophosphamide: a controlled Phase n Trial. J Clin Oncol 1986; 4: 584–588
   PubMed Web of Science ®Google Scholar
• Constine L S, Zagars G, Rubin P, Kligerman M. Protection by WR-2721 of human bone marrow function following irradiation. Int J Radiat Oncol Biol Phys 1986; 12: 1505–1508
   PubMed Web of Science ®Google Scholar
• Speyer J L, Green M D, Kramer E. N Engl J Med 1988; 319: 745–752
   PubMed Web of Science ®Google Scholar
• Creighton A M, Hellmann K, Whitecross S. Nature 1969; 222: 384–385
   PubMed Web of Science ®Google Scholar
• Myers C E. Proceedings of First International Symposium on Organ Related Toxicity, T Tritton. Martinus Nijhoff, 1988; 17–31
   Google Scholar
• Ferrans V J, Herman E H, Hamlin R L. Organ Directed Toxicities of Anticancer Drugs, MPO Hacker, JS Lazo, TR Tritton. Martinus Nijhoff, Boston 1988; 56–63
   Google Scholar
• Speyer J L, Green M D, Zeleniuch-Jacquotte A. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol, in press
   Google Scholar
• Higuchi C M, Thompson J A, Cox T. Lympbokine-activated killer function following autologous bone marrow transplantation for refractory hematological malignancies. Cancer Res 1989; 49: 5509
   PubMed Web of Science ®Google Scholar
• Higuchi C M, Thompson J A, Petersen F B. Toxicity and immunomodulatory effects of interleukin 2 after autologous bone marrow transplantation for hematologic malignancies. Blood, in press
   Google Scholar
• Fefer A, Truitt RL, Sullivan KM. Adoptive cellular therapy: Graft-vs-tumor responses after bone marrow transplantation. Biologic Therapy of Cancer: Principles and Practice, DeVita, Hellman, Rosenberg. JB Lippincott Co., Philadelphia 1991
   Google Scholar
• Wadler S, Schwartz E L. Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. Cancer Res 1990; 30: 3473–3486
   Google Scholar
• Wadler S, Schwartz E L, Goldman M. Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma. J Clin Incol 1989; 7: 1769–1775
   PubMed Web of Science ®Google Scholar
• Wadler S, Wiernik P H. Clinical update on the role of fluorouracil and recombinant interferon alfa-2a in the treatment of colorectal cancer. Semin Oncol 1990; 17: 16–21
   PubMed Web of Science ®Google Scholar
• Wadler S. The role of immunotherapy in colorectal cancer. Semin Oncol 1991; 18: 27–38
   PubMed Web of Science ®Google Scholar
• Lokich J J, Ahlgren J D, Gullo J J. A prospective randomized comparison of continuous infusion fluorouracil with conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. J Clin Oncol 1989; 7: 425–432
   PubMed Web of Science ®Google Scholar
• Sparano J A, Wadler S, Einzig A. Phase I trial of prolonged, continuous infusion 5-fluorouracU and alpha-2a interferon: greater FU dose-intensity and responses in refractory cancer. Proc Am Soc Clin Oncol 1991; 10: 508
   Google Scholar
• Fearon E R, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759–767
   PubMed Web of Science ®Google Scholar
• Vogelstein B, Fearon E R, Hamilton S R. Genetic alterations during colorectal tumor development. N Engl J Med 1988; 319: 525–532
   PubMed Web of Science ®Google Scholar
• Kinzler K W, Nilbert M C, Vogelstein B. Identification of a gene located at chromosome 5q21 that is mutated in colorectal cancers. Science 1991; 251: 1366–1370
   PubMed Web of Science ®Google Scholar
• Itzkowitz S H, Yuan M, Montgomery C K. Expression of Tn, sialosyl Tn, and T antigens in human colon cancer. Cancer Research 1989; 49: 197–204
   PubMed Web of Science ®Google Scholar
• Itzkowitz S H, Bloom E J, Friera A. Mucin-associated antigen expression in colorectal polyps. Gut 1991, in press
   Web of Science ®Google Scholar
• Thor A, Itzkowitz S H, Schlom J. Tumor-associated glycoprotein (TAG-72) expression in ulcerative colitis. Int J Cancer 1989; 43: 810–815
   PubMed Web of Science ®Google Scholar
• Itzkowitz S H, Bloom E J, Kokal W A. Sialosyl-Tn: A novel mucin antigen associated with prognosis in colorectal cancer patients. Cancer 1990; 66: 1960–1966
   PubMed Web of Science ®Google Scholar
• Bresalier R S, Niv Y, Byrd J C. Mucin production by human colonic carcinoma cells correlates with their metastatic potential in animal models of colon cancer metastasis. J Clin Invest 1991; 87: 1037–1045
   PubMed Web of Science ®Google Scholar
• Ogata S, Itzkowitz S H. Effect of a cancer-associated mucin on natural killer (NK) cell function. Proc Am Assoc Cancer Res 1991; 32: 234
   Google Scholar
• Keraeny N, Golbey R. A chemotherapeutic approach to colorectal carcinoma. la Neoplasms of the Colon Rectum and Anus, MR Stearns, Jr. John Wiley, New York 1980; 155–168
   Google Scholar
• Arbuck S G. Overview of clinical trials using 5-fluorouracil and leucovorin for the treatment of colorectal cancer. Cancer 1989; 63: 1036–1044, 6 suppl
   PubMed Web of Science ®Google Scholar
• Lien W M, Ackerman N B. The blood supply of experimental liver metastases. II. A microcirculatory study of the normal and tumor vessels of the liver with the use of perfused silicone rubber. Surgery 1970; 68(2)334–340
   PubMed Web of Science ®Google Scholar
• Sigurdson E R, Ridge J A, Kemeny N, Daly J M. Tumor and liver drug uptake following hepatic artery and portal vein infusion. J Clin Oncol 1987; 5(11)1836–1840
   PubMed Web of Science ®Google Scholar
• Ensminger W D, Gyves J W. Clinical pharmacology of hepatic arterial chemotherapy. Semin Oncol 1983; 10: 176–182
   PubMed Web of Science ®Google Scholar
• Niederhuber J E, Ensminger W, Gyves J W. Regional chemotherapy of colorectal cancer metastatic to the liver. Cancer 1984; 53: 1336–1343
   PubMed Web of Science ®Google Scholar
• Balch C M, Urist M M. Intraarterial chemotherapy for colorectal liver metastases using a totally implantable drug infusion pump. Rec Res Cancer Res 1986; 100: 123–147
   Google Scholar
• Kemeny N, Daly J, Oderman P. Hepatic artery pump infusion toxicity and results in patients with metastatic colorectal carcinoma. J Clin Oncol 1984; 2: 595–600
   PubMed Web of Science ®Google Scholar
• Shepard K V, Levin B, Karl R C. Therapy for metastatic colorectal cancer with hepatic artery infusion chemotherapy using a subcutaneous implanted pump. J Clin Oncol 1985; 3: 161–169
   PubMed Web of Science ®Google Scholar
• Kemeny N, Daly J, Reichman B. Intrahepatic or systemic infusion of fluorodeoxyuridtne in patients with liver metastases from colorectal carcinoma. Ann Intern Med 1987; 107: 459–465
   PubMed Web of Science ®Google Scholar
• Hohn D, Stagg R, Friedman M. A randomized trial of continuous intravenous vs hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver. J Clin Oncol 1989; 7(11)1646–1654
   PubMed Web of Science ®Google Scholar
• Change A E, Schneider P D, Sugarbaker P H. A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg 1987; 206(6)685–693
   PubMed Web of Science ®Google Scholar
• Martin JK, Jr, O'Connell M J, Wieand H S. Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal Cancer. Arch Surg 1990; 125(8)1022–1027
   PubMed Web of Science ®Google Scholar
• Cohen A M, Schaeffer N, Higgins J. Treatment of metastatic colorectal cancer with hepatic artery combination chemotherapy. Cancer 1986; 57(6)1115–1117
   PubMed Web of Science ®Google Scholar
• Seiter K, Kemeny N, Cohen A. A randomized trial of hepatic arterial FUDR + mitomycin + BCNU versus FUDR alone in previously-treated patients with liver metastases from colorectal cancer. Proc Am Soc Clin Oncol 1991; 10: 140
   Google Scholar
• Kemeny N, Cohen A, Bertino J R. Continuous intrahepatic infusion of floxuridine and leucovorin through an implantable pump for the treatment of liver metastases from colorectal carcinoma. Cancer 1990; 65(11)2446–2450
   PubMed Web of Science ®Google Scholar
• Hohn DC., Stagg R C, Price D C. Avoidance of gastroduodenal toxicity in patients receiving hepatic arterial 5-fluoro-2′- deox-yuridine. J Clin Oncol 1985; 3: 1257–1260
   PubMed Web of Science ®Google Scholar
• Hohn D C, Melnick J, Stagg R. Biliary sclerosis in patients receiving hepatic arterial infusions of floxuridine. J Clin Oncol 1985; 3: 98–102
   PubMed Web of Science ®Google Scholar
• Doria MI, Jr, Shepard K V, Levin B. Liver pathology following hepatic arterial infusion chemotherapy. Cancer 1986; 58: 855–861
   PubMed Web of Science ®Google Scholar
• Seiter K, Kemeny N, Berger M. A randomized trial of intrahepatic infusion of FUDR with dexamethasone versus FUDR alone in the treatment of metastatic colorectal cancer. Proc Am Soc Clin Oncol 1990; 9: 108
   Google Scholar
• Von Roemeling R, Hrushesky W J. Circadian patterning of continuous floxuridine infusion reduces toxicity and allows higher dose intensity in patients with widespread cancer. J Clin Oncol 1989; 7(11)1710–1719
   PubMed Web of Science ®Google Scholar
• Stagg R J, Venook A P, Chase J L. Alternating hepatic intraarterial floxuridine and fluorouracil: a less toxic regimen for treatment of liver metastases from colorectal cancer. J Natl Cancer Inst 1991; 83(6)423–428
   PubMed Web of Science ®Google Scholar
• Safi F, Bittner R, Roscher R. Regional chemotherapy for hepatic metastases of colorectal carcinoma (continuous intraarterial versus continuous intraarterial/intravenous therapy). Cancer 1989; 64(2)379–387
   PubMed Web of Science ®Google Scholar
• Kunkel H G, Mannik M, Williams R C. Individual antigenic specificity of isolated antibodies. Science 1963; 140: 1218–1219
   PubMed Web of Science ®Google Scholar
• Bona C A, Kohler H. Anti-idiotypic antibodies and internal images. Monoclonal and Anti-idiotypic Antibodies: Probes for Receptor Structure and Function, JC Venter, CM Fraser, J Lindstrom. Alan R Liss, New York 1984; 141–150
   Google Scholar
• Kohler H. The immune network revisited. Idiotypy in Biology and Medicine, H Kohler, J Urbain, P Cazenave. Academic Press, New York 1984; 3–28
   Google Scholar
• Herlyn D, Wettendorf M, Schmoll E. Anti-Id immunization of cancer patients: Modulation of immune responses. Proc Natl Acad Sci (USA) 1987; 84: 8055–8059
   PubMed Web of Science ®Google Scholar
• Ferrone S, Chen Z J, Yang. Active specific immunotherapy with murine anti-idiotypic monoclonal antibodies which bear the internal image of the human high molecular weight melanoma-associated antigen (HMW-MAA). Proc Ann Meet Am Assoc Cancer Res 1990; 31: 474
   Google Scholar
• Bhattacharya-Chatterjee M, Pride M W, Seon B K, Kohler H. Id vaccines against human T cell acute lymphoblastic leukemia (T-ALL). I. Generation and characterization of biologically active monoclonal anti-idiotypes. J Immunol 1987; 139: 1354–1360
   PubMed Web of Science ®Google Scholar
• Bhattacharya-Chatterjee M, Chatterjee S K, Vasile S. Id vaccines against human T cell leukemia, n. Generation and characterization of a monoclonal Id cascade (Ab1, Ab2 and Ab3). J Immunol 1988; 141: 1398–1403
   PubMed Web of Science ®Google Scholar
• Bhattacharya-Chatterjee M, Mukerjee S, Biddle W. Murine monoclonal anti-Id antibody as a potential network antigen for human carcinoembryonic antigen. J Immunol 1990; 145: 2758–2765
   PubMed Web of Science ®Google Scholar
• Miller R A, Hart S, Samoszuk M. Shared idiotypes expressed by human B cell lymphomas. N Engl J Med 1989; 321: 851–857
   PubMed Web of Science ®Google Scholar
• Chatterjee M, Barcos M, Han. Shared idiotype expression by chronic lymphocytic leukemia and B-cell lymphoma. Blood 1990; 76: 1825–1829
   PubMed Web of Science ®Google Scholar
• Stewart J SW, Hird J V, Snook D. Intraperitoneal131I-and 90Y-labeled monoclonal antibodies for ovarian cancer: pharmacokinetics and normal tissue dosimetry. Int J Cancer 1988; 3: 71
   Google Scholar
• Colcher D, Esteban J, Carrasquillo J A. Complementation of intracavitary and intravenous administration of a monoclonal antibody (B72.3) in patients. Cancer Res 1987; 47: 4218
   PubMed Web of Science ®Google Scholar
• Epenetos A A, Hooker G, Krausz T. Antibody-guided irradiation of malignant acites in ovarian cancer: A new therapeutic method possessing specificity against cancer cells. Obstet Gynecol 1986; 68: 719
   Google Scholar
• Binet S, Fellows A, Meininger V. In situ analysis of the action of Navelbine on various types of microtubules using immunofluorescence. Semin Oncol 1989; 16(2, Suppl 4)5–8
   PubMed Web of Science ®Google Scholar
• Depierre A, Lemarie E, Dabouis G, Gamier G. Efficacy of Navelbine (NVB) in non-small cell lung cancer. Semin Oncol 1989; 16(2 Suppl 4)26–29
   PubMed Web of Science ®Google Scholar
• Fumoleau P, Delgado F M, Delozier T. Phase II trial with Navelbine in advanced breast cancer: Preliminary results. Proc ASCO 1990; 9: 21
   Google Scholar
• Bruno S, Mickiewicz E, Fernandez O. Phase II trial with Navelbine in the treatment of advanced breast cancer patients. Proc 15th International Cancer Congress. J Cancer Res Clin Oncol 1990; 116, Suppl
   Google Scholar
• Spielmann M. Pilot Phase II study with Navelbine (NVB)-Adriamycin (ADR) combination in advanced breast cancer. Proc ASCO 1991; 10: 55
   Google Scholar
• Dienas V. Phase II study of Navelbine (NVB) and fluorouracil (FU) in metastatic breast cancer using group sequential design. 13th Annual Breast Cancer Symposium. (Abstr 65), San Antonio, TX, November, 1990
   Google Scholar